ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
PLx Pharma Receives FDA Approval of SNDAs for Two VAZALORE Dosages americanpharmaceuticalreview
March 04, 2021PLx Pharma announced the U.S. Food and Drug Administration (FDA) approved supplemental new drug applications (sNDAs) for its lead products, VAZALORE? 325 mg and VAZALORE? 81 mg (referred to together as VAZALORE), the first novel, liquid-filled aspirin ... -
PLx Pharma Submits sNDAs for VAZALORE americanpharmaceuticalreview
November 26, 2020PLx Pharma announced two chemistry and manufacturing control (CMC) supplemental New Drug Applications (sNDAs), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as VAZALORE), have been submitted to the U.S. Food and Drug ...
Pharma Sources Insight January 2025
